INTEGRA LIFESCIENCES HOLDINGS CORP Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax of -$56.05 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax · last filed 2026-02-26
- INTEGRA LIFESCIENCES HOLDINGS CORP other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for the quarter ending 2021-12-31 was $68.09M.
- INTEGRA LIFESCIENCES HOLDINGS CORP other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2025 was -$56.05M, a 189.49% decline from fiscal 2024.
- INTEGRA LIFESCIENCES HOLDINGS CORP other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2024 was $62.64M.
- INTEGRA LIFESCIENCES HOLDINGS CORP other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2023 was -$22.07M, a 121.15% decline from fiscal 2022.
- INTEGRA LIFESCIENCES HOLDINGS CORP other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2022 was $104.35M, a 53.03% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$56.05M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $62.64M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | -$22.07M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $104.35M 10-K · filed 2025-02-25 | |||
| 2021-12-31 | $68.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $68.19M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $100.00K 10-Q · filed 2022-07-27 | $100.00K 10-Q · filed 2021-11-02 | ||
| 2020-12-31 | -$96.84M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | -$13.67M 10-K · filed 2022-02-24 | |||
| 2018-12-31 | $11.71M 10-K · filed 2021-02-23 | |||
| 2017-12-31 | -$3.42M 10-K · filed 2020-02-21 | |||
| 2016-12-31 | $1.87M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |